Scholarlink

Background <p>Multimodal analgesia (MMA) combines different analgesic methods, such as non-steroidal inflammatory drugs (NSAIDs), acetaminophen, and regional anesthesia techniques, to optimize pain control while minimizing opioid use. Dinalbuphine sebacate (DS), a long-acting prodrug of nalbuphine, was chosen due to its potential to enhance MMA strategies. The aim of this study is to evaluate the effectiveness of DS in MMA for video-assisted thoracoscopic surgery (VATS).</p> Methods <p>Sixty participants were randomly and equally assigned to either the MMA regimen containing DS (DS group) or placebo (placebo group). After anesthesia induction, all participants received ultrasound-guided thoracic paravertebral block (TPVB), and DS or placebo was injected into the gluteus medius muscle on the operated side. Intravenous patient-controlled analgesia (IVPCA) with fentanyl was provided for breakthrough pain postoperatively. The primary outcome was postoperative fentanyl consumption over three days. Statistical tests included Student’s <i>t</i>-test, chi-square test, and Fisher’s exact test.</p> Results <p>Finally, 57 participants were assigned to either the DS group (<i>n</i> = 28) or the placebo group (<i>n</i> = 29). The mean fentanyl consumption over three days was significantly lower in the DS group (283 ± 70&#xa0;µg) compared to the placebo group (708 ± 190&#xa0;µg, <i>P</i> &lt; 0.001). Pain interference with daily life was significantly lower in the DS group at one week (28.57% vs. 86.2%, <i>P</i> &lt; 0.001) and one month postoperatively (10.71% vs. 48.28%, <i>P</i> = 0.003). Pain intensity during movement was significantly lower in the DS group at one week (2.07 ± 0.61 vs. 4.00 ± 0.56, <i>P</i> &lt; 0.001) and one month (0.64 ± 0.35 vs. 2.10 ± 0.4, <i>P</i> &lt; 0.001).</p> Conclusions <p>By providing superior analgesia, reducing opioid requirements, improving functional recovery and its long-lasting effect after discharge, DS enhanced postoperative MMA for VATS.</p> Trial registration <p>ClinicalTrials.gov Identifier, NCT04962152; Date: 14/07/2021.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Dinalbuphine sebacate on postoperative multimodal analgesic strategy in video-assisted thoracoscopic surgery: a double-blind randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月17日

查看全文
  • Hung-Te Hsu,
  • Chao-Wei Ma,
  • Po-Chih Chang,
  • Yi-Wei Kuo,
  • Tz-Ping Gau,
  • Yu-Wei Liu,
  • Yen-Chin Liu,
  • Shah-Hwa Chou,
  • Kuang-I Cheng

摘要

Background

Multimodal analgesia (MMA) combines different analgesic methods, such as non-steroidal inflammatory drugs (NSAIDs), acetaminophen, and regional anesthesia techniques, to optimize pain control while minimizing opioid use. Dinalbuphine sebacate (DS), a long-acting prodrug of nalbuphine, was chosen due to its potential to enhance MMA strategies. The aim of this study is to evaluate the effectiveness of DS in MMA for video-assisted thoracoscopic surgery (VATS).

Methods

Sixty participants were randomly and equally assigned to either the MMA regimen containing DS (DS group) or placebo (placebo group). After anesthesia induction, all participants received ultrasound-guided thoracic paravertebral block (TPVB), and DS or placebo was injected into the gluteus medius muscle on the operated side. Intravenous patient-controlled analgesia (IVPCA) with fentanyl was provided for breakthrough pain postoperatively. The primary outcome was postoperative fentanyl consumption over three days. Statistical tests included Student’s t-test, chi-square test, and Fisher’s exact test.

Results

Finally, 57 participants were assigned to either the DS group (n = 28) or the placebo group (n = 29). The mean fentanyl consumption over three days was significantly lower in the DS group (283 ± 70 µg) compared to the placebo group (708 ± 190 µg, P < 0.001). Pain interference with daily life was significantly lower in the DS group at one week (28.57% vs. 86.2%, P < 0.001) and one month postoperatively (10.71% vs. 48.28%, P = 0.003). Pain intensity during movement was significantly lower in the DS group at one week (2.07 ± 0.61 vs. 4.00 ± 0.56, P < 0.001) and one month (0.64 ± 0.35 vs. 2.10 ± 0.4, P < 0.001).

Conclusions

By providing superior analgesia, reducing opioid requirements, improving functional recovery and its long-lasting effect after discharge, DS enhanced postoperative MMA for VATS.

Trial registration

ClinicalTrials.gov Identifier, NCT04962152; Date: 14/07/2021.